The toolkit offers advice on how national public health authorities could engage with primary care prescribers so as to promote appropriate and responsible use of antibiotics. The toolkit contains template materials and some suggested key messages for health professionals, idea...s for awareness raising activities, and suggested tactics for getting the messages across to both primary care providers and patients regarding prudent use of antibiotics.
more
March 2020
This document provides a high-level mapping of outbreak stages with guidance on how to time the minimum uptake of different interventions that have been recommended by Africa CDC, driven by evidence and science.
Este documento de orientación se basa en la investigación de la actividad de los medios sociales relacionados con el uso de antibióticos a nivel de la UE, así como en una encuesta sobre las actividades de los medios sociales de las organizaciones asociadas a la EAAD, en su mayoría organizacione...s paraguas de la UE de pacientes y profesionales de la salud. La investigación demostró que ya existe cierta actividad en los medios sociales sobre el uso prudente de los antibióticos y que están surgiendo algunos posibles influenciadores. Análogamente, la encuesta de los asociados de la EAAD en toda la UE mostró que los encuestados están empezando a participar activamente en las plataformas de los medios sociales.
more
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centres and is meant to be accessible to healthcare workers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 isolation centre either within an existing facility ...or as a standalone centre.
more
Available in English, French, Portuguese and Arabic
Successful immunization of a critical mass of the African population with one or several safe and efficacious COVID-19 vaccines.Key objectives1. Accelerate African involvement in the clinical development of a vaccine. 2. Ensur...e African countries can access a sufficient share of the global vaccine supply.3. Remove barriers to widespread delivery and uptake of effective vaccines across Africa.
more
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clinical trials is an essential step to ensure that sufficient data is generated on the safety and efficac...y of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
ASLM in collaboration with the Africa Centres for Disease Control and Prevention, and in partnership with the Clinton Health Access Initiative, Amref and Last Mile Health present the Quality Assurance Framework for SARS-CoV-2 Antigen Rapid Testing for Diagnosis of COVID-19. This framework aims to pr...ovide general technical guidance to African Union Members States on the rollout, establishment, implementation, monitoring, and evaluation of SARS-CoV-2 Ag RDT interventions so as to effectively and efficiently detect, control and minimise errors in the performance of COVID-19 laboratory testing processes. It describes the core components for quality assurance, resources mobilisation and advocacy for scale up, monitoring, evaluation, learning and accountability for SARS-CoV-2 implementation.
more
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership and continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill a...nd Melinda Gates Foundation and the Mastercard Foundation. These partners have helped to shape and drive the continent’s strategic response to the COVID-19 pandemic and have offered support to ensure the continent receives a fair and equitable share of the COVID-19 vaccine without delay.
We look forward to continuing and deepening our partnership for the benefit of the public health of Africa.
more
Many African countries were amongst the most rapid to respond to the emerging threat of COVID-19, implementing large-scale interventions at very early stages of their epidemic. As demonstrated in this document using very simple models, this rapid mobilization and timeliness of implementing control m...easures is likely to be an important determinant of their success. Indeed, as these measures were relaxed, subsequent waves of disease have been observed in many countries including South Africa, Kenya, Tunisia, Morocco, Sudan and the Democratic Republic of Congo (DRC) where such waves have severely impacted the health system by straining the supply of oxygen and ICU beds and inflicting a heavy toll on healthcare workers, often necessitating the re-imposition of control measures.
more
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.
In 2007, WHO warned that infectious diseases are emerging and re-emerging at a rate that has not been seen before. The potential for infectious diseases to spread rapidly results in high morbidity and mortality, causing a potential global public health treat of major concern.
Several factors are ...contributing to the (re)emergence of infectious diseases such as population growth, living in close contact with animals, frequent travelling, poverty, destructive ecological changes due to economic development and land use and climate change result in global warming.
Especially Africa is at a threat for (re)emerging infectious diseases due to the huge population growth (expected to reach 2.5 billion by 2050) with rapid urbanisation. Additionally, people across and beyond the continent are excessively mobile which is combined with a weak health system. Moreover, the risk of (re)emerging infectious disease is further heightened by three newly adopted continental initiatives: African Continental Free Trade Area, Free Movement of Persons and African Passport and Single African Air Transport Market.
more
Here you can find the latest reports
Le cadre de surveillance basé sur les événements est destiné à être utilisé par les autorités et les
agences responsables de la surveillance et de l'intervention. Ce cadre sert de cadre pour guider les
parties prenantes intéressées par la mise en œuvre de la surveillance basée sur le...s événements (SBÈ)
en utilisant une approche multisectorielle axée sur l'approche « Une seule santé ». À cette fin, le
document est organisé en chapitres et annexes interconnectés qui peuvent être modifiés et adaptés,
selon les besoins, par les utilisateurs.
Il s'agit d'une version révisée du « Cadre pour la surveillance basée sur les événements » original qui
a été publié en 2018. Ce cadre ne remplace aucun autre matériel SBÈ disponible, mais s'appuie plutôt
sur des documents pertinents ou connexes existants et sert de guide pratique pour la mise en œuvre
de l'SBÈ en Afrique. Ce cadre est conforme à la troisième édition de l'évaluation externe conjointe de
l'OMS pour les indicateurs suivants : systèmes d'alerte précoce renforcés capables de détecter les
événements importants pour la santé publique et la sécurité sanitaire (indicateur D2.1) ; amélioration
de la communication et de la collaboration entre les secteurs et entre les niveaux d'autorité nationaux,
intermédiaires et locaux d'intervention en matière de santé publique en matière de surveillance des
événements importants pour la santé publique (indicateur D2.2) ; et amélioration de la capacité
d'analyse des données aux niveaux national et intermédiaire ( Indicateur D2.3). Au fur et à mesure
que les pays commenceront à mettre en œuvre et à démontrer la fonctionnalité SBÈ, ils garantiront
une augmentation des scores EEC et des progrès vers le respect des exigences décrites dans l'RSI
(Règlement sanitaire international).
En outre, dans les États membres de l'Union africaine qui ont adopté la Surveillance et réponse
intégrées aux maladies (SRIM), ce document complète et peut améliorer la mise en œuvre de l'SRIM,
en particulier pour la 3e édition (2019) qui inclut des composants liés à l'SBÈ.
more
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more
The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr...ess the emergency.
MAAP reviewed 819,584 AMR records from 2016-2019, from 205 laboratories across Burkina Faso, Cameroon, Eswatini, Gabon, Ghana, Kenya, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe. MAAP also reviewed data from 327 hospital and community pharmacies and 16 national-level AMC datasets.
more